Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 0 |
PubMed (GeneRIF) for id: 128434
3 results
Results by year
Filters applied: . Clear all
Page 1
VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
Biochem Biophys Res Commun. 2023 May 28;658:107-115. doi: 10.1016/j.bbrc.2023.03.073. Epub 2023 Apr 1.
Biochem Biophys Res Commun. 2023.
PMID: 37030064
High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
Liu H, Zhang Z, Zhen P, Zhou M.
Liu H, et al.
J Immunol Res. 2021 Jan 8;2021:6657012. doi: 10.1155/2021/6657012. eCollection 2021.
J Immunol Res. 2021.
PMID: 33506057
Free PMC article.
Item in Clipboard
VSTM2L is a novel secreted antagonist of the neuroprotective peptide Humanin.
Rossini L, Hashimoto Y, Suzuki H, Kurita M, Gianfriddo M, Scali C, Roncarati R, Franceschini D, Pollio G, Trabalzini L, Terstappen GC, Matsuoka M, Caricasole A.
Rossini L, et al.
FASEB J. 2011 Jun;25(6):1983-2000. doi: 10.1096/fj.10-163535. Epub 2011 Mar 10.
FASEB J. 2011.
PMID: 21393573
Item in Clipboard
Cite
Cite